USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $-0.33 | $-0.29 | $-0.28 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $0.00 | - | $0.00 |
Aldeyra Therapeutics's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 8 | $-0.33 | $-0.55 | $-0.23 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 10 | $-1.36 | $-2.26 | $-0.99 |
| Dec 2023 | 9 | $-1.12 | $-2.08 | $-0.08 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 2 / 0 | $-0.36 | $-0.37 | $-0.37 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 3 / 1 | $-1.32 | $-1.32 | $-1.31 |
| Dec 2023 | 3 / 0 | $-1.11 | $-1.09 | $-1.10 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 6 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 7 | $0.00 | $0.00 | $0.00 |
| Dec 2023 | 9 | $33.54M | $3.00M | $78.90M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 5, 2022 | Mar 2022 | $-0.31 | $-0.29 | 6.45% |
| Mar 17, 2022 | Dec 2021 | $-0.28 | $-0.27 | 3.57% |
| Oct 28, 2021 | Sep 2021 | $-0.25 | $-0.27 | -7.61% |
| Aug 5, 2021 | Jun 2021 | $-0.23 | $-0.28 | -24.28% |
| May 6, 2021 | Mar 2021 | $-0.26 | $-0.25 | 2.95% |
| Mar 11, 2021 | Dec 2020 | $-0.30 | $-0.30 | 0.43% |
| Nov 5, 2020 | Sep 2020 | $-0.27 | $-0.23 | 15.53% |
| Aug 6, 2020 | Jun 2020 | $-0.35 | $-0.25 | 27.91% |
| May 7, 2020 | Mar 2020 | $-0.46 | $-0.34 | 26.80% |
| Mar 12, 2020 | Dec 2019 | $-0.70 | $-0.48 | 31.10% |
| Nov 7, 2019 | Sep 2019 | $-0.56 | $-0.69 | -23.68% |
| Aug 8, 2019 | Jun 2019 | $-0.49 | $-0.49 | -0.64% |
| May 9, 2019 | Mar 2019 | $-0.44 | $-0.58 | -32.33% |
| Mar 8, 2019 | Dec 2018 | $-0.43 | $-0.39 | 9.07% |
| Nov 14, 2018 | Sep 2018 | $-0.48 | $-0.52 | -9.47% |
| Aug 9, 2018 | Jun 2018 | $-0.43 | $-0.46 | -8.24% |
| May 15, 2018 | Mar 2018 | $-0.38 | $-0.43 | -14.15% |
| Mar 29, 2018 | Dec 2017 | $-0.32 | $-0.36 | -13.39% |
| Nov 9, 2017 | Sep 2017 | $-0.35 | $-0.32 | 9.22% |
| Aug 7, 2017 | Jun 2017 | $-0.37 | $-0.35 | 5.41% |
| May 15, 2017 | Mar 2017 | $-0.35 | $-0.37 | -7.25% |
| Mar 30, 2017 | Dec 2016 | $-0.46 | $-0.35 | 23.08% |
| Nov 14, 2016 | Sep 2016 | $-0.41 | $-0.38 | 7.32% |
| Aug 10, 2016 | Jun 2016 | $-0.44 | $-0.41 | 7.24% |
| May 9, 2016 | Mar 2016 | $-0.50 | $-0.51 | -2.51% |
| Mar 30, 2016 | Dec 2015 | $-0.37 | $-0.46 | -24.32% |
| Nov 12, 2015 | Sep 2015 | $-0.30 | $-0.35 | -16.67% |
| Aug 11, 2015 | Jun 2015 | $-0.35 | $-0.27 | 22.86% |
| May 13, 2015 | Mar 2015 | $-0.38 | $-0.32 | 15.79% |
| Mar 19, 2015 | Dec 2014 | $-0.40 | $-0.30 | 25.00% |
| Nov 10, 2014 | Sep 2014 | $-0.32 | $-0.36 | -12.50% |
| Aug 4, 2014 | Jun 2014 | $-0.53 | $-1.56 | -194.34% |
| May 28, 2014 | Mar 2014 | - | $-0.18 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 17, 2022 | Dec 2021 | $-1.10 | $-1.07 | - |
| Mar 11, 2021 | Dec 2020 | $-1.09 | $-1.12 | - |
| Mar 12, 2020 | Dec 2019 | $-2.45 | $-2.24 | - |
| Mar 8, 2019 | Dec 2018 | $-1.86 | $-1.80 | - |
| Mar 29, 2018 | Dec 2017 | $-1.35 | $-1.40 | - |
| Mar 30, 2017 | Dec 2016 | - | $-1.65 | - |
| Mar 30, 2016 | Dec 2015 | - | $-1.40 | - |
| Mar 19, 2015 | Dec 2014 | - | $-2.40 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 5, 2022 | Mar 2022 | $0.00 | - | - |
| Mar 17, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Oct 28, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 5, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 6, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 11, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 5, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 6, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 7, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 12, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 7, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 8, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 9, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Mar 8, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Nov 14, 2018 | Sep 2018 | $0.00 | $0.00 | - |
| Aug 9, 2018 | Jun 2018 | $0.00 | $0.00 | - |
| May 15, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Mar 29, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Nov 9, 2017 | Sep 2017 | - | $0.00 | - |
| Aug 7, 2017 | Jun 2017 | - | $0.00 | - |
| May 15, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 30, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 14, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 10, 2016 | Jun 2016 | - | $0.00 | - |
| May 9, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 30, 2016 | Dec 2015 | - | $0.00 | - |
| Nov 12, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 11, 2015 | Jun 2015 | - | $0.00 | - |
| May 13, 2015 | Mar 2015 | - | $0.00 | - |
| Mar 19, 2015 | Dec 2014 | - | $0.00 | - |
| Nov 10, 2014 | Sep 2014 | - | $0.00 | - |
| Aug 4, 2014 | Jun 2014 | - | $0.00 | - |
| May 28, 2014 | Mar 2014 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 17, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Mar 11, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 12, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 8, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Mar 29, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Mar 30, 2017 | Dec 2016 | - | $0.00 | - |
| Mar 30, 2016 | Dec 2015 | - | $0.00 | - |
| Mar 19, 2015 | Dec 2014 | - | $0.00 | - |
ALDX's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Aldeyra Therapeutics's next quarterly earnings is $-0.33, with a low EPS estimation of $-0.55, and a high estimation of $-0.23.
Over the last 1 month, EPS estimates have seen 2 upward revisions and 0 downward. The EPS 1 month trend is $-0.36, the last 2 month trend is $-0.37, and the 3 month trend is $-0.37.
Based on analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Aldeyra Therapeutics's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.
ALDX's earnings per share (EPS) was $-0.29, beating the consensus analysts forecast of $-0.31 by 6.45%.
The EPS was lower than the previous fiscal quarter (Dec 2021) by 7.41%, and lower than the same period a year before (Mar 2021) by 16.00%.
The company reported a net income of $-16.79M.Aldeyra Therapeutics's previous annual earnings date was Mar 17, 2022 for its fiscal year ended Dec 31, 2021.
ALDX's earnings per share (EPS) was $-1.07, beating the consensus analysts forecast of $-1.10 by -2.73% , and higher than the previous year's EPS (Dec 2020) by -4.46%.
Revenues were $0.00.
The company reported a net income of $-57.78B.
Aldeyra Therapeutics reported a free cash flow of $-42.56B for its fiscal year, compared to $-37.49M a year ago.
The company ended the fiscal year with $15.86M in total debt, an increase of 3.46% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
